Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Sep. 30, 2022 | Nov. 04, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2022 | |
Document Transition Report | false | |
Entity File Number | 001-38546 | |
Entity Registrant Name | NEURONETICS, INC. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 33-1051425 | |
Entity Address, Address Line One | 3222 Phoenixville Pike | |
Entity Address, City or Town | Malvern | |
Entity Address, State or Province | PA | |
Entity Address, Postal Zip Code | 19355 | |
City Area Code | 610 | |
Local Phone Number | 640-4202 | |
Title of 12(b) Security | Common Stock ($0.01 par value) | |
Trading Symbol | STIM | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 27,221,490 | |
Entity Central Index Key | 0001227636 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q3 | |
Amendment Flag | false | |
Entity Ex Transition Period | false |
Balance Sheets
Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 73,698 | $ 94,141 |
Accounts receivable, net | 11,963 | 7,706 |
Inventory | 8,573 | 6,563 |
Current portion of net investments in sales-type leases | 1,874 | 2,198 |
Current portion of prepaid commission expense | 1,871 | 1,559 |
Current portion of note receivables | 80 | 74 |
Prepaid expenses and other current assets | 3,037 | 3,090 |
Total current assets | 101,096 | 115,331 |
Property and equipment, net | 2,109 | 1,220 |
Operating lease right-of-use assets | 3,459 | 3,884 |
Net investments in sales-type leases | 1,617 | 1,697 |
Prepaid commission expense | 7,305 | 6,763 |
Long-term note receivable | 94 | 10,110 |
Other assets | 3,555 | 2,218 |
Total Assets | 119,235 | 141,223 |
Current liabilities: | ||
Accounts payable | 2,350 | 4,299 |
Accrued expenses | 11,493 | 8,233 |
Deferred revenue | 1,732 | 2,501 |
Current portion of operating lease liabilities | 818 | 670 |
Current portion of long-term debt, net | 8,750 | |
Total current liabilities | 25,143 | 15,703 |
Long-term debt, net | 27,009 | 35,335 |
Deferred revenue | 981 | 1,471 |
Operating lease liabilities | 3,111 | 3,539 |
Total Liabilities | 56,244 | 56,048 |
Commitments and contingencies (Note 17) | ||
Stockholders' Equity: | ||
Preferred stock, $0.01 par value: 10,000 shares authorized; no shares issued or outstanding on September 30, 2022, and December 31, 2021 | ||
Common stock, $0.01 par value: 200,000 shares authorized; 27,060 and 26,395 shares issued and outstanding on September 30, 2022, and December 31, 2021, respectively | 270 | 264 |
Additional paid-in capital | 400,323 | 393,644 |
Accumulated deficit | (337,602) | (308,733) |
Total Stockholders' Equity | 62,991 | 85,175 |
Total Liabilities and Stockholders' Equity | $ 119,235 | $ 141,223 |
Balance Sheets (Parenthetical)
Balance Sheets (Parenthetical) - $ / shares shares in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Balance Sheets | ||
Preferred stock, par value | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 10,000 | 10,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 200,000 | 200,000 |
Common stock, shares issued | 27,060 | 26,395 |
Common stock, shares outstanding | 27,060 | 26,395 |
Statements of Operations
Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Statements of Operations | ||||
Revenues | $ 16,498 | $ 13,799 | $ 47,008 | $ 40,290 |
Cost of revenues | 3,570 | 3,144 | 11,093 | 8,115 |
Gross Profit | 12,928 | 10,655 | 35,915 | 32,175 |
Operating expenses: | ||||
Sales and marketing | 11,643 | 9,827 | 37,977 | 27,431 |
General and administrative | 6,391 | 6,435 | 19,125 | 19,220 |
Research and development | 2,348 | 1,575 | 6,197 | 6,179 |
Total operating expenses | 20,382 | 17,837 | 63,299 | 52,830 |
Loss from Operations | (7,454) | (7,182) | (27,384) | (20,655) |
Other (income) expense: | ||||
Interest expense | 1,061 | 993 | 3,039 | 2,955 |
Other income, net | (906) | (24) | (1,554) | (53) |
Net Loss | $ (7,609) | $ (8,151) | $ (28,869) | $ (23,557) |
Net loss per share of common stock outstanding, basic | $ (0.28) | $ (0.31) | $ (1.08) | $ (0.94) |
Net loss per share of common stock outstanding, diluted | $ (0.28) | $ (0.31) | $ (1.08) | $ (0.94) |
Weighted-average common shares outstanding, basic | 26,965 | 26,301 | 26,797 | 25,179 |
Weighted-average common shares outstanding, diluted | 26,965 | 26,301 | 26,797 | 25,179 |
Statements of Changes in Stockh
Statements of Changes in Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Total |
Beginning balance at Dec. 31, 2020 | $ 191 | $ 302,842 | $ (277,540) | $ 25,493 |
Beginning balance, shares at Dec. 31, 2020 | 19,114 | |||
Share-based awards and options exercises | $ 11 | 1,581 | 1,592 | |
Share-based awards and options exercises, shares | 1,076 | |||
Issuance of common stock | $ 56 | 80,515 | 80,571 | |
Issuance of common stock (in shares) | 5,566 | |||
Share-based compensation expense | 2,196 | 2,196 | ||
Net Loss | (7,881) | (7,881) | ||
Ending balance at Mar. 31, 2021 | $ 258 | 387,134 | (285,421) | 101,971 |
Ending balance, shares at Mar. 31, 2021 | 25,756 | |||
Beginning balance at Dec. 31, 2020 | $ 191 | 302,842 | (277,540) | 25,493 |
Beginning balance, shares at Dec. 31, 2020 | 19,114 | |||
Net Loss | (23,557) | |||
Ending balance at Sep. 30, 2021 | $ 263 | 391,910 | (301,097) | 91,076 |
Ending balance, shares at Sep. 30, 2021 | 26,335 | |||
Beginning balance at Mar. 31, 2021 | $ 258 | 387,134 | (285,421) | 101,971 |
Beginning balance, shares at Mar. 31, 2021 | 25,756 | |||
Share-based awards and options exercises | $ 4 | 707 | 711 | |
Share-based awards and options exercises, shares | 411 | |||
Share-based compensation expense | 2,009 | 2,009 | ||
Net Loss | (7,525) | (7,525) | ||
Ending balance at Jun. 30, 2021 | $ 262 | 389,850 | (292,946) | 97,166 |
Ending balance, shares at Jun. 30, 2021 | 26,167 | |||
Share-based awards and options exercises | $ 1 | 99 | 100 | |
Share-based awards and options exercises, shares | 168 | |||
Share-based compensation expense | 1,961 | 1,961 | ||
Net Loss | (8,151) | (8,151) | ||
Ending balance at Sep. 30, 2021 | $ 263 | 391,910 | (301,097) | 91,076 |
Ending balance, shares at Sep. 30, 2021 | 26,335 | |||
Beginning balance at Dec. 31, 2021 | $ 264 | 393,644 | (308,733) | 85,175 |
Beginning balance, shares at Dec. 31, 2021 | 26,395 | |||
Share-based awards and options exercises | $ 3 | 6 | 9 | |
Share-based awards and options exercises, shares | 322 | |||
Share-based compensation expense | 2,252 | 2,252 | ||
Net Loss | (10,838) | (10,838) | ||
Ending balance at Mar. 31, 2022 | $ 267 | 395,902 | (319,571) | 76,598 |
Ending balance, shares at Mar. 31, 2022 | 26,717 | |||
Beginning balance at Dec. 31, 2021 | $ 264 | 393,644 | (308,733) | 85,175 |
Beginning balance, shares at Dec. 31, 2021 | 26,395 | |||
Net Loss | (28,869) | |||
Ending balance at Sep. 30, 2022 | $ 270 | 400,323 | (337,602) | 62,991 |
Ending balance, shares at Sep. 30, 2022 | 27,060 | |||
Beginning balance at Mar. 31, 2022 | $ 267 | 395,902 | (319,571) | 76,598 |
Beginning balance, shares at Mar. 31, 2022 | 26,717 | |||
Share-based awards and options exercises | $ 1 | 42 | 43 | |
Share-based awards and options exercises, shares | 139 | |||
Share-based compensation expense | 2,203 | 2,203 | ||
Net Loss | (10,422) | (10,422) | ||
Ending balance at Jun. 30, 2022 | $ 268 | 398,147 | (329,993) | 68,422 |
Ending balance, shares at Jun. 30, 2022 | 26,856 | |||
Share-based awards and options exercises | $ 2 | (2) | ||
Share-based awards and options exercises, shares | 204 | |||
Share-based compensation expense | 2,178 | 2,178 | ||
Net Loss | (7,609) | (7,609) | ||
Ending balance at Sep. 30, 2022 | $ 270 | $ 400,323 | $ (337,602) | $ 62,991 |
Ending balance, shares at Sep. 30, 2022 | 27,060 |
Statements of Changes in Stoc_2
Statements of Changes in Stockholders' Equity (Parenthetical) $ in Thousands | 3 Months Ended |
Mar. 31, 2021 USD ($) | |
Statements of Changes in Stockholders' Equity (Deficit) | |
Issuance of common stock, issuance costs | $ 401 |
Statements of Cash Flows
Statements of Cash Flows - USD ($) $ in Thousands | 9 Months Ended | 12 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Cash Flows from Operating Activities: | |||
Net loss | $ (28,869) | $ (23,557) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Depreciation and amortization | 1,044 | 768 | |
Share-based compensation | 6,633 | 6,166 | |
Non-cash interest expense | 513 | 484 | |
Cost of rental units purchased by customers | 92 | 137 | |
Changes in certain assets and liabilities: | |||
Accounts receivable, net | (4,257) | (3,097) | |
Inventory | (2,299) | (1,870) | |
Net investments in sales-type leases | 381 | 341 | |
Prepaid commission expense | (854) | (602) | |
Prepaid expenses and other assets | 176 | (453) | |
Accounts payable | (2,199) | (840) | |
Accrued expenses | 3,260 | (405) | |
Deferred revenue | (1,260) | (531) | |
Net Cash Used in Operating Activities | (27,639) | (23,459) | $ (28,000) |
Cash Flows from Investing Activities: | |||
Purchases of property and equipment and capitalized software | (2,766) | (1,552) | |
Repayment (Issuance) of promissory note | 10,000 | ||
Repayment (Issuance) of promissory note | (7,486) | ||
Net Cash provided by (used in) Investing Activities | 7,234 | (9,038) | |
Cash Flows from Financing Activities: | |||
Payments of debt issuance costs | (90) | ||
Proceeds from exercises of stock options | 52 | 2,403 | |
Proceeds from the issuance of common stock | 80,972 | ||
Payments of common stock offering issuance costs | (401) | ||
Net Cash (used in) Provided by Financing Activities | (38) | 82,974 | |
Net (Decrease) Increase in Cash and Cash Equivalents | (20,443) | 50,477 | |
Cash and Cash Equivalents, Beginning of Period | 94,141 | 48,957 | 48,957 |
Cash and Cash Equivalents, End of Period | 73,698 | 99,434 | $ 94,141 |
Supplemental disclosure of cash flow information: | |||
Cash paid for interest | 2,525 | 2,471 | |
Transfer of Inventory to PP&E | 285 | 235 | |
Supplemental disclosure of non-cash investing and financing activities: | |||
Purchases of property and equipment and capitalized software in accounts payable and accrued expenses | $ 251 | 398 | |
Reduction of accounts receivable in long-term note receivable | $ 2,514 |
Description of Business
Description of Business | 9 Months Ended |
Sep. 30, 2022 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Description of Business | 1. DESCRIPTION OF BUSINESS Neuronetics, Inc., or the Company, is a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. The Company’s first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system was cleared in 2008 by the United States Food and Drug Administration, or the FDA, to treat adult patients with major depressive disorder, or MDD, who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Our NeuroStar Advanced Therapy system was also cleared in 2022 by the FDA to treat people suffering from obsessive-compulsive disorder as well as for the treatment of comorbid anxiety symptoms for adults with MDD suffering from anxiety symptoms (“anxious depression”). NeuroStar Advanced Therapy is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. COVID-19 The Company is continuing to monitor the impact of the COVID-19 pandemic on all aspects of its business and geographies, including how it will continue to impact the Company’s customers, supply chain, employees and other business partners. While the Company experienced significant disruptions in March 2020 through the end of September 30, 2022 from the COVID-19 pandemic, it is unable to predict the full impact that the pandemic may have on its financial condition, results of operations and cash flows due to numerous uncertainties. These uncertainties include the scope, severity and duration of the ongoing pandemic, the actions taken to contain the pandemic or mitigate its impact and the direct and indirect economic effects of the pandemic, vaccination rates, effectiveness of treatments, and containment measures, among others. The pandemic has significantly adversely impacted global economic activity and has contributed to significant volatility and negative pressure in financial markets, and may contribute to periods of economic uncertainty in the future. Liquidity As of September 30, 2022, the Company had cash and cash equivalents of $73.7 million and an accumulated deficit of $337.6 million. The Company incurred negative cash flows from operating activities of $27.6 million for the nine months ended September 30, 2022 and $28.0 million for the year ended December 31, 2021. The Company has incurred operating losses since its inception, and management anticipates that its operating losses will continue in the near term as the Company continues to invest in sales, marketing and product development activities. The Company’s primary sources of capital to date have been proceeds from its initial public offering (“IPO”) of common stock, private placements of its convertible preferred securities, borrowings under its credit facility, proceeds from its secondary public offering of common stock and revenues from sales of its products. As of September 30, 2022, the Company had $35.0 million of borrowings outstanding under its credit facility, which has a final maturity in February 2025 |
Basis of Presentation
Basis of Presentation | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
Basis of Presentation | 2. BASIS OF PRESENTATION The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASUs, promulgated by the Financial Accounting Standards Board, or FASB. Interim Financial Statements The accompanying unaudited interim financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the United States Securities and Exchange Commission, or SEC, which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the accompanying balance sheets and statements of operations and stockholders’ equity and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. Unaudited interim results of operations and cash flows for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the full year. Unaudited interim financial statements and footnotes should be read in conjunction with the audited financial statements and footnotes included in the Company’s Form 10-K filed with the SEC on March 8, 2022, wherein a more complete discussion of significant accounting policies and certain other information can be found. Use of Estimates The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company’s business and evolving market conditions, including those related to the COVID-19 pandemic, and given the subjective element of the estimates and assumptions made, actual results may differ materially from estimated results. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company’s complete summary of significant accounting policies can be found in “Note 3. Summary of Significant Accounting Policies” in the audited financial statements included in the Company’s Form 10-K filed with the SEC on March 8, 2022. |
Recent Accounting Pronouncement
Recent Accounting Pronouncements | 9 Months Ended |
Sep. 30, 2022 | |
New Accounting Pronouncements And Changes In Accounting Principles [Abstract] | |
Recent Accounting Pronouncements | 4. RECENT ACCOUNTING PRONOUNCEMENTS New Accounting Standards Not Yet Adopted by the Company In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments “Topic 326” ASU 2019-04, ASU 2019-05, Financial Instruments - Credit Losses (Topic 326) : Targeted Transition Relief , was issued to provide entities that have certain instruments within the scope of ASC 326 with an option to irrevocably elect the fair value option under ASC 825-10, Financial Instruments - Overall , applied on an instrument-by-instrument basis for eligible instruments ASU 2019-10, Topic 326, Topic 815, and Topic 842 amends the mandatory effective date for Topic 326. These ASUs are effective for fiscal years beginning after December 15, 2022 for entities that are eligible to be defined by the SEC as a smaller reporting company. The Company is a smaller reporting company. Although the impact upon adoption will depend on the financial instruments held by the Company at that time, the Company does not anticipate a significant impact on its financial statements based on the instruments currently held and its historical trend of bad debt expense relating to trade accounts receivable. Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our unaudited interim financial statements. |
Fair Value Measurement and Fina
Fair Value Measurement and Financial Instruments | 9 Months Ended |
Sep. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurement and Financial Instruments | 5. FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS The carrying values of cash equivalents, accounts receivable, prepaids and other current assets, and accounts payable on the Company’s balance sheets approximated their fair values as of September 30, 2022 and December 31, 2021 due to their short-term nature. The carrying values of the Company’s credit facility approximated its fair value as of September 30, 2022 and December 31, 2021 due to its variable interest rate. The carrying value of the Company’s note receivable approximated its fair value as of December 31, 2021 due to its variable interest rate. Certain of the Company’s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: Level 1 Inputs are quoted prices for identical instruments in active markets. Level 2 Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. Level 3 Inputs are unobservable and reflect the Company’s own assumptions, based on the best information available, including the Company’s own data . The following tables set forth the carrying amounts and fair values of the Company’s financial instruments as of September 30, 2022 and December 31, 2021 (in thousands): September 30, 2022 Fair Value Measurement Based on Quoted Significant Prices In other Significant Active Observable Unobservable Carrying Markets Inputs Inputs Amount Fair Value (Level 1) (Level 2) (Level 3) Assets Money market funds (cash equivalents) $ 69,405 $ 69,405 $ 69,405 $ — $ — December 31, 2021 Fair Value Measurement Based on Quoted Significant Prices In other Significant Active Observable Unobservable Carrying Markets Inputs Inputs Amount Fair Value (Level 1) (Level 2) (Level 3) Assets Money market funds (cash equivalents) $ 91,236 $ 91,236 $ 91,236 $ — $ — |
Accounts Receivable
Accounts Receivable | 9 Months Ended |
Sep. 30, 2022 | |
Receivables [Abstract] | |
Accounts Receivable | 6. ACCOUNTS RECEIVABLE The following table presents the composition of accounts receivable, net as of September 30, 2022 and December 31, 2021 (in thousands): September 30, December 31, 2022 2021 Gross accounts receivable - trade $ 13,754 $ 9,168 Less: Allowances for doubtful accounts (1,791) (1,462) Accounts receivable, net $ 11,963 $ 7,706 |
Property and Equipment and Capi
Property and Equipment and Capitalized Software | 9 Months Ended |
Sep. 30, 2022 | |
Property Plant And Equipment [Abstract] | |
Property and Equipment and Capitalized Software | 7. PROPERTY AND EQUIPMENT AND CAPITALIZED SOFTWARE The following table presents the composition of property and equipment, net as of September 30, 2022 and December 31, 2021 (in thousands): September 30, December 31, 2022 2021 Laboratory equipment $ 466 $ 249 Office equipment 508 497 Computer equipment and software 1,711 1,598 Manufacturing equipment 344 341 Leasehold improvements 1,422 471 Rental equipment 575 601 Property and equipment, gross 5,026 3,757 Less: Accumulated depreciation (2,917) (2,537) Property and equipment, net $ 2,109 $ 1,220 As of September 30, 2022 and December 31, 2021, the Company had capitalized software costs, net of $3.7 million and $2.5 million, respectively, which are included in “Prepaid expenses and other current assets” and “Other assets” on the balance sheet. Depreciation and amortization expense was $0.4 million and $0.2 million for the three months ended September 30, 2022 and 2021, respectively, and $1.0 million and $0.8 million for the nine months ended September 30, 2022 and 2021, respectively. |
Note Receivable
Note Receivable | 9 Months Ended |
Sep. 30, 2022 | |
Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract] | |
Note Receivable | 8. NOTE RECEIVABLE On September 29, 2021, Neuronetics, Inc. the Company entered into an exclusive, five-year master sales agreement (the “Commercial Agreement”) with Check Five, LLC d/b/a Success TMS (“Success TMS”). In connection with the Commercial Agreement, the Company agreed to loan Success TMS the principal amount of $10.0 million for a period of five years pursuant to a secured promissory note (the “Note”). The Note bore interest at a floating rate equal to the prime rate plus 6.00% per annum. The Note included an interest-only period through October 1, 2022, after which time Success TMS was required to make monthly payments of principal and interest. Under the terms of the Note, the Company had received a first priority security interest in substantially all of the assets of Success TMS. Success TMS has also granted the Company an observer seat on the Board of Managers of Success TMS. In the Note, Success TMS made certain representations and warranties and was required to comply with certain customary affirmative and negative covenants during the term of the Note. On April 29, 2022, the Company entered into a Subordination Agreement (the “Subordination Agreement”) with ZW Partners, LLC, a New Jersey limited liability company (“ZW Partners”), pursuant to which the Company agreed to subordinate its rights under the Note to the rights of ZW Partners under a revolving promissory note, dated as of April 29, 2022 (the “Senior Note”), issued by Success TMS to ZW Partners in an amount up to $10.0 million. As a result, payments in respect of the Note were subordinate and subject in right and time of payment to payment in full of the Senior Note, and ZW Partners’ liens and security interests upon the collateral securing both the Senior Note and the Note are superior in priority to the Company’s liens and security interests upon such collateral. Under the Agreement, the Company had the right to purchase, at par, the entire aggregate amount of debt under the Senior Note at any time. On July 14, 2022, Success TMS repaid in full the Note issued on September 29, 2021 with a cash payment of $10.5 million, which included all outstanding principal, prepayment premium and accrued but unpaid interest. The repayment extinguished the Note in its entirety and terminated the Subordination Agreement entered into by the Company and ZW Partners. Interest income recognized by the Company was $0.5 million and $1.0 million for the three and nine months ended September 30, 2022, respectively. |
Leases
Leases | 9 Months Ended |
Sep. 30, 2022 | |
Leases [Abstract] | |
Leases | 9. LEASES Lessee: The Company has operating leases for its corporate headquarters, a training facility and office equipment, including copiers. The Company leases an approximately 32,000 square foot facility in Malvern, Pennsylvania for its corporate headquarters, which includes office and warehouse space. The Company leases an approximately 9,600 square foot facility in Charlotte, North Carolina as a training facility for its NeuroStar Advanced Therapy Systems. The Company does not currently have any finance leases or executed leases that have not yet commenced. Operating lease rent expense was $0.2 million and $0.2 million for the three months ended September 30, 2022 and 2021, respectively, and $0.6 million and $0.4 million for the nine months ended September 30, 2022 and 2021, respectively. As of September 30, 2022, the weighted-average remaining lease term of operating leases was 5.3 years and the weighted-average discount rate was 7.1%. The following table presents the supplemental cash flow information as a lessee related to leases (in thousands): Nine Months Ended September 30, 2022 September 30, 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 632 $ 526 The following table sets forth by year the required future payments of operating lease liabilities (in thousands): September 30, 2022 Remainder of 2022 $ 209 2023 852 2024 875 2025 898 2026 921 Thereafter 999 Total lease payments 4,754 Less imputed interest (825) Present value of operating lease liabilities $ 3,929 Lessor sales-type leases: Certain customers have purchased NeuroStar Advanced Therapy Systems on a rent-to-own basis. The lease term is three The following table sets forth the profit recognized on sales-type leases (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Profit recognized at commencement, net $ 122 $ 262 $ 543 $ 543 Interest income — — — — Total sales-type lease income $ 122 $ 262 $ 543 $ 543 The following table sets forth a maturity analysis of the undiscounted lease receivables related to sales-type leases (in thousands): September 30, 2022 Remainder of 2022 $ 605 2023 1,572 2024 858 2025 368 2026 88 Total sales-type lease receivables $ 3,491 As of September 30, 2022, the carrying amount of the lease receivables is $3.5 million. The Company does not have any unguaranteed residual assets. Lessor operating leases: NeuroStar Advanced Therapy Systems sold for which collection is not probable are accounted for as operating leases. For the three months ended September 30, 2022 and 2021, the Company recognized operating lease income of $0.07 million and $0.03 million, respectively. For the nine months ended September 30, 2022 and 2021, the Company recognized operating lease income of $0.2 million and $0.2 million, respectively. The Company maintained Rental Equipment, net of $0.5 million and $0.6 million as of September 30, 2022 and December 31, 2021, respectively, which are included in “Property and equipment, net” on the balance sheet. Rental equipment depreciation expense was $0.02 million and $0.01 million for the three months ended September 30, 2022 and 2021, respectively, and $0.07 million and $0.03 million for the nine months ended September 30, 2022 and 2021. |
Prepaid Commission Expense
Prepaid Commission Expense | 9 Months Ended |
Sep. 30, 2022 | |
Amortization Of Deferred Charges [Abstract] | |
Prepaid Commission Expense | 10. PREPAID COMMISSION EXPENSE The Company pays a commission on both NeuroStar Advanced System sales and Treatment Session sales. Since the commission paid for System sales is not commensurate with the commission paid for Treatment Sessions, the Company capitalizes commission expense associated with NeuroStar Advanced Therapy System sales commissions paid that is incremental to specifically anticipated future Treatment Session orders. In developing this estimate, the Company considered its historical Treatment Session sales and customer retention rates, as well as technology development life cycles and other industry factors. These costs are periodically reviewed for impairment. NeuroStar Advanced Therapy System commissions are deferred and amortized on a straight-line basis over a seven-year period equal to the average customer term, which the Company deems to be the expected period of benefit for these costs. On the Company’s balance sheets, the current portion of capitalized contract costs is represented by the current portion of prepaid commission expense, while the long-term portion is included in prepaid commission expense. Amortization expense was $0.5 million and $0.3 million for the three months ended September 30, 2022 and 2021, respectively, and $1.3 million and $0.9 million for the nine months ended September 30, 2022 and 2021, respectively. |
Accrued Expenses
Accrued Expenses | 9 Months Ended |
Sep. 30, 2022 | |
Payables And Accruals [Abstract] | |
Accrued Expenses | 11. ACCRUED EXPENSES The following table presents the composition of accrued expenses as of September 30, 2022 and December 31, 2021 (in thousands): September 30, December 31, 2022 2021 Compensation and related benefits $ 8,022 $ 5,090 Consulting and professional fees 760 537 Research and development expenses 637 388 Sales and marketing expenses 246 268 Warranty 337 306 Sales and other taxes payable 558 664 Other 933 980 Accrued expenses $ 11,493 $ 8,233 |
Deferred Revenue
Deferred Revenue | 9 Months Ended |
Sep. 30, 2022 | |
Deferred Revenue [Abstract] | |
Deferred Revenue | 12. DEFERRED REVENUE Payment terms typically require payment upon shipment or installation of the System and additional payments as access codes for Treatment Sessions are delivered, which can span several years after the System is first delivered and installed. The timing of revenue recognition compared to billings and cash collections typically results in accounts receivable. However, sometimes customer advances and deposits might be required for certain customers and are recorded as contract liabilities (deferred revenue). For multi-year agreements, the Company generally invoices customers annually at the beginning of each annual coverage period and recognizes revenue over the term of the coverage period. As of September 30, 2022, the Company expects to recognize approximately the following percentages of deferred revenue by year: Revenue Year: Recognition Remainder of 2022 25 % 2023 40 % 2024 25 % 2025 8 % 2026 2 % Total 100 % Customers For the three months ended September 30, 2022 and 2021, one customer accounted for more than 10% of the Company’s revenues, respectively. For the nine months ended September 30, 2022 and 2021, one customer accounted for more than 10% of the Company’s revenues, respectively. |
Debt
Debt | 9 Months Ended |
Sep. 30, 2022 | |
Debt Disclosure [Abstract] | |
Debt | 13. DEBT The following table presents the composition of debt as of September 30, 2022 and December 31, 2021 (in thousands): September 30, December 31, 2022 2021 Outstanding principal $ 35,000 $ 35,000 Accrued final payment fees 1,925 1,925 Less debt discounts (1,166) (1,590) Total debt, net 35,759 35,335 Less current portion (8,750) — Long-term debt, net $ 27,009 $ 35,335 For the three months ended September 30, 2022, the Company recognized interest expense of $1.1 million, of which $0.9 million was cash and $0.2 million was non-cash interest expense related to the amortization of deferred debt issuance costs and accrual of final payment fees. For the three months ended September 30, 2021, the Company recognized interest expense of $1.0 million, of which $0.8 million was cash and $0.2 million was non-cash interest expense related to the amortization of deferred debt issuance costs and accrual of final payment fees. For the nine months ended September 30, 2022, the Company recognized interest expense of $3.0 million, of which $2.5 million was cash and $0.5 million was non-cash interest expense related to the amortization of deferred debt issuance costs and accrual of final payment fees. Solar Credit Facility On March 2, 2020, the Company entered into a loan and security agreement with Solar Capital Ltd., or Solar, as collateral agent, and other lenders defined in the agreement, for a credit facility, or the Solar Facility, that replaced the Company’s previous $35.0 million credit facility with Oxford Finance LLC, or Oxford, and such facility, the Oxford Facility. The Solar Facility originally permitted the Company to borrow up to an aggregate amount of $50.0 million in two tranches of term loans, a “Term A Loan” and “Term B Loan.” On March 2, 2020, the Company borrowed an aggregate amount of $35.0 million, which was the aggregate amount available under the Term A Loan portion of the Solar Facility. The Term A Loan portion of the Solar Facility matures, and all amounts borrowed thereunder are due, on February 28, 2025. Under the Term B Loan portion of the Solar Facility, the Company is permitted to borrow, at its election, up to an aggregate amount of $15.0 million, (i) upon the Company achieving a specified amount of trailing twelve Each of the Term A Loan and Term B Loan accrue interest from the date of borrowing through the date of repayment at a floating per annum rate of interest, which resets monthly and is equal to 7.65% plus the greater of (a) 1.66% or (b) the rate per annum rate published by the Intercontinental Exchange Benchmark Administration Ltd. The Term A Loan and the Term B Loan both include an interest-only period through March February 2023 In addition to the principal and interest payments due under the Solar Facility, the Company is required to pay a final payment fee to Solar due upon the earlier of prepayment, acceleration or the maturity date of the Term A Loan or Term B Loan portion of the Solar Facility equal to 5.50% of the principal amount of the term loans actually funded. The Company is accruing the final payment fees using the effective interest rate, with a charge to non-cash interest expense, over the term of borrowing. If the Company prepays either of the Term A Loan or Term B Loan prior to their respective scheduled maturities, the Company will also be required to pay prepayment fees to Solar equal to 3% of the principal amount of such term loan then-prepaid if prepaid on or before the first anniversary of funding, 2% of the principal amount of such term loan then-prepaid if prepaid after the first anniversary and on or before the second anniversary of funding, or 1% of the principal amount of such term loan then-prepaid if prepaid after the second anniversary of funding of the principal amounts borrowed. The Company is also required to pay Solar an exit fee upon the occurrence, prior to March 2, 2030, of (a) any liquidation, dissolution or winding up of the Company, (b) transaction that results in a person obtaining control over the Company, (c) the Company achieving $100 million in trailing twelve month net product revenue or (d) the Company achieving $125 million in trailing twelve month net product revenue. The exit fee for liquidation, dissolution, winding up or change of control of the Company is equal to 4.50% of the principal amount of the term loans actually funded. The exit fee for achieving either $100 million or $125 million in trailing twelve-month net product revenue is equal to 2.25% of the principal amount of the term loans actually funded or, if both net product revenue milestones are achieved, 4.50% of the principal amount of the term loans actually funded. The exit fee is capped at 4.50% of the principal amount of the term loans actually funded. The Company’s obligations under the Solar Facility are secured by a first priority security interest in substantially all of its assets, including its intellectual property. The loan and security agreement requires the Company to comply with certain financial covenants, including the attainment of a minimum trailing net revenue amount beginning on December 31, 2020, as well as customary affirmative and negative covenants. The Solar Facility contains events of default, including, without limitation, events of default upon: (i) failure to make payment pursuant to the terms of the agreement; (ii) violation of covenants; (iii) material adverse changes to the Company’s business; (iv) attachment or levy on the Company’s assets or judicial restraint on its business; (v) insolvency; (vi) material cross-defaults; (vii) significant judgments, orders or decrees for payments by the Company not covered by insurance; (viii) incorrectness of representations and warranties; (ix) incurrence of subordinated debt; (x) a termination or breach of a guaranty; (xi) revocation of governmental approvals necessary for the Company to conduct its business; and (xii) failure by the Company to maintain a valid and perfected lien on the collateral securing the borrowing. The Solar Facility includes subjective acceleration clauses which permit the lenders to accelerate the maturity date under certain circumstances, including, but not limited to, material adverse effects on a Company’s financial status or otherwise. On December 8, 2020, the Company, Solar Capital Ltd., and our other lenders defined in the Solar Facility, executed an amendment to the Solar Facility (the “Solar Amendment”). The Solar Amendment divided the aggregate Term B Loan borrowing amount of $15.0 million allowable upon our achievement of specific trailing twelve-month net product revenue targets into three separate $5.0 million tranches (“Amended Term B Loan”, “Term C Loan” and “Term D Loan”). The three tranches are available through June 20, 2021, December 20, 2021, and June 20, 2022, respectively, based on the achievement of agreed upon trailing twelve-month net product revenue targets for each tranche. The Solar Amendment also reduced the trailing twelve-month net product revenue requirement for the Amended Term B Loan portion of the facility. Subject to certain conditions, the Company has the ability to extend the interest only period on the initial Term A Loan to 36 months from 24 months upon achieving the revenue targets associated with the Amended Term B Loan. The Company was required to pay an amendment fee of $0.1 million to Solar, which was recognized as a deferred debt issuance cost as of December 31, 2020 that will be amortized to interest expense using the effective interest method. On February 15, 2022, the Company, SLR Investment Corp. (formerly known as Solar Capital Ltd.) (“Solar”), and our other lenders defined in the Solar Facility, executed an amendment to the Solar Facility and the Solar Amendment (the “2022 Solar Amendment”). The 2022 Solar Amendment waived any default under the Solar Facility and Solar Amendment that resulted from the Company’s failure to comply with the minimum monthly trailing twelve months net product revenue financial covenant, beginning with the testing period for the calendar month ending December 31, 2021 and continuing to the execution date of the 2022 Solar Amendment; (ii) decreased the amount of trailing twelve months net product revenue that the Company is required to achieve, for testing periods on and from the calendar month ending January 31, 2022; (iii) modified the definition of the fourth draw period with respect to the Company’s ability to borrow the Term D Loan portion of the Solar Facility, such that after giving effect to the 2022 Solar Amendment, the Term D Loan portion of the Solar Facility is no longer available to be drawn by the Company; and (iv) modified the definition of interest only extension conditions to allow commencement of loan principal amortization under the Solar Facility to be extended to March 1, 2023. The Company was required to pay an amendment fee of $0.06 million to Solar, which has been recognized as a deferred debt issuance cost as of March 31, 2022 that will be amortized to interest expense using the effective interest method. As of September 30, 2022, the Company is in compliance with all covenants in the Solar Facility and is projected to be in compliance with the reduced minimum revenue covenant amounts going forward. |
Common Stock
Common Stock | 9 Months Ended |
Sep. 30, 2022 | |
Equity [Abstract] | |
Common Stock | 14. COMMON STOCK Common Stock Offering On February 2, 2021, we closed on our public offering and sale (the “Offering”) of our common stock in which we issued and sold 5,566,000 shares of our common stock, which included shares pursuant to an option granted to underwriters to purchase additional shares, at a public offering price of $15.50 per share. We received net proceeds of $80.6 million after deducting underwriting discounts, commissions and offering expenses. Common Stock The following table summarizes the total number of shares of the Company’s common stock issued and reserved for issuance as of September 30, 2022 and December 31, 2021 (in thousands): September 30, 2022 December 31, 2021 Shares of common stock issued 27,060 26,395 Shares of common stock reserved for issuance for: Common stock warrants outstanding 75 75 Stock options outstanding 1,424 1,499 Restricted stock units outstanding 4,060 2,124 Shares available for grant under stock incentive plan 1,067 2,037 Shares available for sale under employee stock purchase plan 1,063 799 Total shares of common stock issued and reserved for issuance 34,749 32,929 Common Stock Warrants The following tables summarize the Company’s outstanding common stock warrants as of September 30, 2022, and December 31, 2021: September 30, 2022 Warrants Outstanding (in thousands) Exercise Price Expiration Date 14 $ 19.55 Dec-2022 20 $ 9.73 Aug-2023 20 $ 9.73 Mar-2024 21 $ 9.73 Dec-2024 75 December 31, 2021 Warrants Outstanding (in thousands) Exercise Price Expiration Date 14 $ 19.55 Dec-2022 20 $ 9.73 Aug-2023 20 $ 9.73 Mar-2024 21 $ 9.73 Dec-2024 75 |
Loss Per Share
Loss Per Share | 9 Months Ended |
Sep. 30, 2022 | |
Earnings Per Share [Abstract] | |
Loss Per Share | 15. LOSS PER SHARE The Company’s basic loss per common share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. The Company’s restricted stock awards (non-vested shares) are issued and outstanding at the time of grant but are excluded from the Company’s computation of weighted-average shares outstanding in the determination of basic loss per share until vesting occurs. A net loss cannot be diluted, so when the Company is in a net loss position, basic and diluted loss per common share are the same. If in the future the Company achieves profitability, the denominator of a diluted earnings per common share calculation will include both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options, non-vested restricted stock units and non-vested performance restricted stock units using the treasury stock method, along with the effect, if any, from the potential conversion of outstanding securities, such as convertible preferred stock. The following potentially dilutive securities outstanding as of September 30, 2022 and 2021 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands): September 30, 2022 2021 Stock options 1,424 1,567 Non-vested performance restricted stock units 395 395 Non-vested restricted stock units 3,665 1,647 Common stock warrants 75 75 |
Share-Based Compensation
Share-Based Compensation | 9 Months Ended |
Sep. 30, 2022 | |
Disclosure Of Compensation Related Costs Share-based Payments [Abstract] | |
Share-Based Compensation | 16. SHARE-BASED COMPENSATION The amount of share-based compensation expense recognized by the Company by location in its statements of operations for the three and nine months ended September 30, 2022 and 2021 is as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Cost of revenues $ 35 $ 23 $ 94 56 Sales and marketing 1,074 515 3,258 1,608 General and administrative 939 1,368 2,950 4,368 Research and development 130 55 331 134 Total $ 2,178 $ 1,961 $ 6,633 $ 6,166 2018 Equity Incentive Plan In June 2018, the Company adopted the 2018 Equity Incentive Plan, or 2018 Plan, which authorized the issuance of up to 1.4 million shares, subject to an annual 4% increase based on the number of shares of common stock outstanding, in the form of restricted stock, stock appreciation rights and stock options to the Company’s directors, employees and consultants. The amount and terms of grants are determined by the Company’s board of directors. All stock options granted to date have had exercise prices equal to the fair value, as determined by the closing price as reported by the Nasdaq Global Market, of the underlying common stock on the date of grant. The contractual term of stock options is up to 10 years, and stock options are exercisable in cash or as otherwise determined by the board of directors. Generally, stock options vest 25% upon the first anniversary of the date of grant and the remainder ratably monthly thereafter for 36 months. Restricted stock units generally vest ratably in three equal installments on the first, second and third anniversaries of the grant date. Performance restricted stock units (“PRSUs”) generally vest based on appreciation of the Company’s common stock to a certain price as determined by the Company’s board of directors measured using a trailing 30-day volume weighted average price of a share of the Company’s common stock. The fair value of the PRSU awards are determined using a risk neutral Monte Carlo simulation valuation model. As of September 30, 2022, there were 0.6 million shares available for future issuance under the 2018 Plan. 2020 Inducement Incentive Plan In December 2020, the Company adopted the 2020 Inducement Incentive Plan, which authorized the issuance of up to 0.4 million shares, subject to increase by approval of the Company’s board of directors, in the form of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards and other stock awards to eligible employees who satisfy the standards for inducement grants under Nasdaq Global Market rules. In March 2022, the Company’s board of directors approved an additional 500,000 shares for the issuance under the plan. An individual who previously served as an employee or director of the Company is not eligible to receive awards under this plan. The amount and terms of grants are determined by the Company’s board of directors. As of September 30, 2022, there were 0.5 million shares available for future issuance under the 2020 Inducement Incentive Plan. Stock Options The following table summarizes the Company’s stock option activity for the nine months ended September 30, 2022: Aggregate Number of Weighted- Weighted- average Shares under average Remaining Intrinsic Option Exercise Price Contractual Value (in thousands) per Option Life (in years) (in thousands) Outstanding at December 31, 2021 1,499 $ 4.01 Granted — $ — Exercised (51) $ 1.01 Forfeited (24) $ 13.41 Outstanding at September 30, 2022 1,424 $ 3.96 7.2 $ 1,260 Exercisable at September 30, 2022 913 $ 4.62 6.9 $ 708 Vested and expected to vest at September 30, 2022 1,424 $ 3.96 7.2 $ 1,260 The Company recognized share-based compensation expense related to stock options of $0.2 million and $0.2 million for the three months ended September 30, 2022 and 2021, respectively, and $0.5 million and $0.6 million for the nine months ended September 30, 2022 and 2021, respectively. As of September 30, 2022, there was $0.7 million of total unrecognized compensation cost related to non-vested stock options which the Company expects to recognize over a weighted-average period of 1.4 years. The total intrinsic value of stock options exercised during the nine months ended September 30, 2022 was $0.1 million. Restricted Stock Units and Performance Restricted Stock Units The following table summarizes the Company’s restricted stock unit and performance restricted stock unit activity for September 30, 2022: Non-vested Weighted- Non-vested Weighted- Restricted average Performance Restricted average Stock Units Grant-date Stock Units Grant-date (in thousands) Fair Value (in thousands) Fair Value Non-vested at December 31, 2021 1,729 $ 7.29 395 $ 6.77 Granted 2,775 $ 3.32 — $ — Vested (613) $ 7.64 — $ — Forfeited (226) $ 6.12 — $ — Non-vested at September 30, 2022 3,665 $ 4.29 395 $ 6.77 The Company recognized $2.0 million and $1.8 million in share-based compensation expense related to the restricted stock units and performance restricted stock units for the three months ended September 30, 2022 and 2021, respectively, and $6.1 million and $5.5 million the nine months ended September 30, 2022 and 2021, respectively. As of September 30, 2022, there was $11.0 million of unrecognized compensation cost related to non-vested restricted stock units and performance restricted stock units, which the Company expects to recognize over a weighted-average period of 1.9 years. The total fair value at the vesting date of restricted stock units and performance restricted stock units vested during the nine months ended September 30, 2022, was $2.2 million. The Company did not grant performance restricted stock units during the period ended September 30, 2022. For the period ended December 31, 2021, the grant-date fair value of the performance restricted stock units was estimated at the time of grant using the following inputs and assumptions in the Monte Carlo simulation valuation model: December 31, 2021 Closing price of common stock $ 15.92 Risk-free interest rate 1.15 % Expected volatility 99.7 % |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2022 | |
Commitments And Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 17. COMMITMENTS AND CONTINGENCIES Legal Matters The Company is subject from time to time to various claims and legal actions arising during the ordinary course of its business. Management believes that there are currently no claims or legal actions that would reasonably be expected to have a material adverse effect on the Company’s results of operations, financial condition, or cash flows. |
Geographical Segment Informatio
Geographical Segment Information | 9 Months Ended |
Sep. 30, 2022 | |
Segments Geographical Areas [Abstract] | |
Geographical Segment Information | 18. GEOGRAPHICAL SEGMENT INFORMATION Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company currently operates in one business segment as it is managed and operated as one business. A single management team that reports to the chief operating decision maker comprehensively manages the entire business. The Company does not operate any material separate lines of business or separate business entities with respect to its products or product development. The following geographic data includes revenue generated from the Company’s third-party distributors. The Company’s revenue was generated in the following geographic regions and by product line for the periods indicated (in thousands): Revenues by Geography Three Months Ended September 30, 2022 2021 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) United States $ 16,244 98 % $ 13,280 96 % International 254 2 % 519 4 % Total revenues $ 16,498 100 % $ 13,799 100 % U.S. Revenues by Product Category Three Months Ended September 30, 2022 2021 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) NeuroStar Advanced Therapy System $ 3,934 24 % $ 2,612 20 % Treatment sessions 11,864 73 % 10,259 77 % Other 446 3 % 409 3 % Total U.S. revenues $ 16,244 100 % $ 13,280 100 % International Revenues by Product Category Three Months Ended September 30, 2022 2021 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) NeuroStar Advanced Therapy System $ 96 38 % $ 306 59 % Treatment sessions 31 12 % 90 17 % Other 127 50 % 123 24 % Total International revenues $ 254 100 % $ 519 100 % Revenues by Geography Nine Months Ended September 30, 2022 2021 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) United States $ 45,893 98 % $ 38,891 97 % International 1,115 2 % 1,399 3 % Total revenues $ 47,008 100 % $ 40,290 100 % U.S. Revenues by Product Category Nine Months Ended September 30, 2022 2021 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) NeuroStar Advanced Therapy System $ 11,959 26 % $ 6,945 18 % Treatment sessions 32,627 71 % 30,688 79 % Other 1,307 3 % 1,258 3 % Total U.S. revenues $ 45,893 100 % $ 38,891 100 % International Revenues by Product Category Nine Months Ended September 30, 2022 2021 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) NeuroStar Advanced Therapy System $ 460 41 % $ 797 57 % Treatment sessions 214 19 % 235 17 % Other 441 40 % 367 26 % Total International revenues $ 1,115 100 % $ 1,399 100 % |
Severance
Severance | 9 Months Ended |
Sep. 30, 2022 | |
Restructuring And Related Activities [Abstract] | |
Severance | 19. SEVERANCE The Company entered into transition agreements outlining the separation with certain former employees during the period ended September 30, 2022 and 2021. In connection with these agreements, the Company recorded $0.0 million and $0.3 million of charges in salary, payroll tax and bonus expenses for the three months ended September 30, 2022 and 2021, respectively, and $0.2 million and $0.5 million for the nine months ended September 30, 2022 and 2021, respectively. For the nine months ended September 30, 2022 and 2021, $0.4 million and $1.1 million of termination benefits were paid associated with the termination of the employees and charged against this liability. As of September 30, 2022 and December 31, 2021, $0.0 million and $0.1 million, respectively, remain in accrued liabilities for the unpaid portion of the separation benefits. |
Risks and Uncertainties
Risks and Uncertainties | 9 Months Ended |
Sep. 30, 2022 | |
Risks and Uncertainties [Abstract] | |
Risks and Uncertainties | 20. RISKS AND UNCERTAINTIES Information About Significant Customers Significant customers are those which represent more than 10% of the Company’s total revenue or are considered significant based on combination of quantitative and qualitative factors during the periods. For each significant customer, revenue as a percentage of total revenue was as follows (in thousands, except for percentages): Nine Months Ended September 30, 2022 2021 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) Customer 1 $ 9,183 20 % $ 8,759 22 % Total $ 9,183 20 % $ 8,759 22 % Accounts receivable outstanding related to these customers as of September 30, 2022 was as follows (in thousands): September 30, 2022 Customer 1 $ 4,886 Total accounts receivable $ 4,886 |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
Interim Financial Statements | Interim Financial Statements The accompanying unaudited interim financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the United States Securities and Exchange Commission, or SEC, which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the accompanying balance sheets and statements of operations and stockholders’ equity and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. Unaudited interim results of operations and cash flows for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the full year. Unaudited interim financial statements and footnotes should be read in conjunction with the audited financial statements and footnotes included in the Company’s Form 10-K filed with the SEC on March 8, 2022, wherein a more complete discussion of significant accounting policies and certain other information can be found. |
Use of Estimates | Use of Estimates The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company’s business and evolving market conditions, including those related to the COVID-19 pandemic, and given the subjective element of the estimates and assumptions made, actual results may differ materially from estimated results. |
Fair Value Measurement and Fi_2
Fair Value Measurement and Financial Instruments (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
Schedule of Carrying Amounts and Fair Values of Financial Instruments | The following tables set forth the carrying amounts and fair values of the Company’s financial instruments as of September 30, 2022 and December 31, 2021 (in thousands): September 30, 2022 Fair Value Measurement Based on Quoted Significant Prices In other Significant Active Observable Unobservable Carrying Markets Inputs Inputs Amount Fair Value (Level 1) (Level 2) (Level 3) Assets Money market funds (cash equivalents) $ 69,405 $ 69,405 $ 69,405 $ — $ — December 31, 2021 Fair Value Measurement Based on Quoted Significant Prices In other Significant Active Observable Unobservable Carrying Markets Inputs Inputs Amount Fair Value (Level 1) (Level 2) (Level 3) Assets Money market funds (cash equivalents) $ 91,236 $ 91,236 $ 91,236 $ — $ — |
Accounts Receivable (Tables)
Accounts Receivable (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Receivables [Abstract] | |
Composition of Accounts Receivable, Net | The following table presents the composition of accounts receivable, net as of September 30, 2022 and December 31, 2021 (in thousands): September 30, December 31, 2022 2021 Gross accounts receivable - trade $ 13,754 $ 9,168 Less: Allowances for doubtful accounts (1,791) (1,462) Accounts receivable, net $ 11,963 $ 7,706 |
Property and Equipment and Ca_2
Property and Equipment and Capitalized Software (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Property Plant And Equipment [Abstract] | |
Summary of Composition of Property and Equipment, Net | The following table presents the composition of property and equipment, net as of September 30, 2022 and December 31, 2021 (in thousands): September 30, December 31, 2022 2021 Laboratory equipment $ 466 $ 249 Office equipment 508 497 Computer equipment and software 1,711 1,598 Manufacturing equipment 344 341 Leasehold improvements 1,422 471 Rental equipment 575 601 Property and equipment, gross 5,026 3,757 Less: Accumulated depreciation (2,917) (2,537) Property and equipment, net $ 2,109 $ 1,220 |
Leases (Tables)
Leases (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Leases [Abstract] | |
Schedule of Supplemental Cash Flow Information as Lessee Related to Leases | The following table presents the supplemental cash flow information as a lessee related to leases (in thousands): Nine Months Ended September 30, 2022 September 30, 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 632 $ 526 |
Schedule of Future Payments of Operating Lease Liabilities | The following table sets forth by year the required future payments of operating lease liabilities (in thousands): September 30, 2022 Remainder of 2022 $ 209 2023 852 2024 875 2025 898 2026 921 Thereafter 999 Total lease payments 4,754 Less imputed interest (825) Present value of operating lease liabilities $ 3,929 |
Schedule of Profit Recognized on Sales-type Leases | The following table sets forth the profit recognized on sales-type leases (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Profit recognized at commencement, net $ 122 $ 262 $ 543 $ 543 Interest income — — — — Total sales-type lease income $ 122 $ 262 $ 543 $ 543 |
Schedule of Maturity Analysis of Undiscounted Lease Receivables Related to Sales-type Leases | The following table sets forth a maturity analysis of the undiscounted lease receivables related to sales-type leases (in thousands): September 30, 2022 Remainder of 2022 $ 605 2023 1,572 2024 858 2025 368 2026 88 Total sales-type lease receivables $ 3,491 |
Accrued Expenses (Tables)
Accrued Expenses (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Payables And Accruals [Abstract] | |
Summary of Composition of Accrued Expenses | The following table presents the composition of accrued expenses as of September 30, 2022 and December 31, 2021 (in thousands): September 30, December 31, 2022 2021 Compensation and related benefits $ 8,022 $ 5,090 Consulting and professional fees 760 537 Research and development expenses 637 388 Sales and marketing expenses 246 268 Warranty 337 306 Sales and other taxes payable 558 664 Other 933 980 Accrued expenses $ 11,493 $ 8,233 |
Deferred Revenue (Tables)
Deferred Revenue (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Deferred Revenue [Abstract] | |
Summary of Percentages of Deferred Revenue by Year | As of September 30, 2022, the Company expects to recognize approximately the following percentages of deferred revenue by year: Revenue Year: Recognition Remainder of 2022 25 % 2023 40 % 2024 25 % 2025 8 % 2026 2 % Total 100 % |
Debt (Tables)
Debt (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Debt Disclosure [Abstract] | |
Summary of Composition of Debt | The following table presents the composition of debt as of September 30, 2022 and December 31, 2021 (in thousands): September 30, December 31, 2022 2021 Outstanding principal $ 35,000 $ 35,000 Accrued final payment fees 1,925 1,925 Less debt discounts (1,166) (1,590) Total debt, net 35,759 35,335 Less current portion (8,750) — Long-term debt, net $ 27,009 $ 35,335 |
Common Stock (Tables)
Common Stock (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Equity [Abstract] | |
Summary of Common Stock Issued and Reserved for Issuance | The following table summarizes the total number of shares of the Company’s common stock issued and reserved for issuance as of September 30, 2022 and December 31, 2021 (in thousands): September 30, 2022 December 31, 2021 Shares of common stock issued 27,060 26,395 Shares of common stock reserved for issuance for: Common stock warrants outstanding 75 75 Stock options outstanding 1,424 1,499 Restricted stock units outstanding 4,060 2,124 Shares available for grant under stock incentive plan 1,067 2,037 Shares available for sale under employee stock purchase plan 1,063 799 Total shares of common stock issued and reserved for issuance 34,749 32,929 |
Summary of Outstanding Warrants | The following tables summarize the Company’s outstanding common stock warrants as of September 30, 2022, and December 31, 2021: September 30, 2022 Warrants Outstanding (in thousands) Exercise Price Expiration Date 14 $ 19.55 Dec-2022 20 $ 9.73 Aug-2023 20 $ 9.73 Mar-2024 21 $ 9.73 Dec-2024 75 December 31, 2021 Warrants Outstanding (in thousands) Exercise Price Expiration Date 14 $ 19.55 Dec-2022 20 $ 9.73 Aug-2023 20 $ 9.73 Mar-2024 21 $ 9.73 Dec-2024 75 |
Loss Per Share (Tables)
Loss Per Share (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Earnings Per Share [Abstract] | |
Schedule of Potentially Dilutive Securities Outstanding Excluded from Diluted Loss Per Share Calculation | The following potentially dilutive securities outstanding as of September 30, 2022 and 2021 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands): September 30, 2022 2021 Stock options 1,424 1,567 Non-vested performance restricted stock units 395 395 Non-vested restricted stock units 3,665 1,647 Common stock warrants 75 75 |
Share-Based Compensation (Table
Share-Based Compensation (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Disclosure Of Compensation Related Costs Share-based Payments [Abstract] | |
Summary of Share-Based Compensation Expense | The amount of share-based compensation expense recognized by the Company by location in its statements of operations for the three and nine months ended September 30, 2022 and 2021 is as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Cost of revenues $ 35 $ 23 $ 94 56 Sales and marketing 1,074 515 3,258 1,608 General and administrative 939 1,368 2,950 4,368 Research and development 130 55 331 134 Total $ 2,178 $ 1,961 $ 6,633 $ 6,166 |
Summary of Stock Option Activity | The following table summarizes the Company’s stock option activity for the nine months ended September 30, 2022: Aggregate Number of Weighted- Weighted- average Shares under average Remaining Intrinsic Option Exercise Price Contractual Value (in thousands) per Option Life (in years) (in thousands) Outstanding at December 31, 2021 1,499 $ 4.01 Granted — $ — Exercised (51) $ 1.01 Forfeited (24) $ 13.41 Outstanding at September 30, 2022 1,424 $ 3.96 7.2 $ 1,260 Exercisable at September 30, 2022 913 $ 4.62 6.9 $ 708 Vested and expected to vest at September 30, 2022 1,424 $ 3.96 7.2 $ 1,260 |
Summary of Restricted Stock Units and Performance Restricted Stock Units Activity | The following table summarizes the Company’s restricted stock unit and performance restricted stock unit activity for September 30, 2022: Non-vested Weighted- Non-vested Weighted- Restricted average Performance Restricted average Stock Units Grant-date Stock Units Grant-date (in thousands) Fair Value (in thousands) Fair Value Non-vested at December 31, 2021 1,729 $ 7.29 395 $ 6.77 Granted 2,775 $ 3.32 — $ — Vested (613) $ 7.64 — $ — Forfeited (226) $ 6.12 — $ — Non-vested at September 30, 2022 3,665 $ 4.29 395 $ 6.77 |
Summary of Inputs and Assumptions used to Estimated Grant-date Fair Value of Performance Restricted Stock Units | The Company did not grant performance restricted stock units during the period ended September 30, 2022. For the period ended December 31, 2021, the grant-date fair value of the performance restricted stock units was estimated at the time of grant using the following inputs and assumptions in the Monte Carlo simulation valuation model: December 31, 2021 Closing price of common stock $ 15.92 Risk-free interest rate 1.15 % Expected volatility 99.7 % |
Geographical Segment Informat_2
Geographical Segment Information (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Summary of Revenue Generated in Geographic Regions for Years Indicated | Revenues by Geography Three Months Ended September 30, 2022 2021 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) United States $ 16,244 98 % $ 13,280 96 % International 254 2 % 519 4 % Total revenues $ 16,498 100 % $ 13,799 100 % Revenues by Geography Nine Months Ended September 30, 2022 2021 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) United States $ 45,893 98 % $ 38,891 97 % International 1,115 2 % 1,399 3 % Total revenues $ 47,008 100 % $ 40,290 100 % |
United States | |
Summary of Revenue Generated in Product Category for Years Indicated | U.S. Revenues by Product Category Three Months Ended September 30, 2022 2021 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) NeuroStar Advanced Therapy System $ 3,934 24 % $ 2,612 20 % Treatment sessions 11,864 73 % 10,259 77 % Other 446 3 % 409 3 % Total U.S. revenues $ 16,244 100 % $ 13,280 100 % U.S. Revenues by Product Category Nine Months Ended September 30, 2022 2021 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) NeuroStar Advanced Therapy System $ 11,959 26 % $ 6,945 18 % Treatment sessions 32,627 71 % 30,688 79 % Other 1,307 3 % 1,258 3 % Total U.S. revenues $ 45,893 100 % $ 38,891 100 % |
International | |
Summary of Revenue Generated in Product Category for Years Indicated | International Revenues by Product Category Three Months Ended September 30, 2022 2021 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) NeuroStar Advanced Therapy System $ 96 38 % $ 306 59 % Treatment sessions 31 12 % 90 17 % Other 127 50 % 123 24 % Total International revenues $ 254 100 % $ 519 100 % International Revenues by Product Category Nine Months Ended September 30, 2022 2021 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) NeuroStar Advanced Therapy System $ 460 41 % $ 797 57 % Treatment sessions 214 19 % 235 17 % Other 441 40 % 367 26 % Total International revenues $ 1,115 100 % $ 1,399 100 % |
Risks and Uncertainties (Tables
Risks and Uncertainties (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Risks and Uncertainties [Abstract] | |
Schedules of Concentration of Risk by Significant Customers | For each significant customer, revenue as a percentage of total revenue was as follows (in thousands, except for percentages): Nine Months Ended September 30, 2022 2021 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) Customer 1 $ 9,183 20 % $ 8,759 22 % Total $ 9,183 20 % $ 8,759 22 % Accounts receivable outstanding related to these customers as of September 30, 2022 was as follows (in thousands): September 30, 2022 Customer 1 $ 4,886 Total accounts receivable $ 4,886 |
Description of Business - Addit
Description of Business - Additional Information (Details) - USD ($) $ in Thousands | 9 Months Ended | 12 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Description Of Business [Line Items] | |||
Cash and cash equivalents | $ 73,698 | $ 94,141 | |
Accumulated deficit | 337,602 | 308,733 | |
Cash flows from operating activities | 27,639 | $ 23,459 | $ 28,000 |
$35.0 Million Credit Facility | Oxford Finance LLC | |||
Description Of Business [Line Items] | |||
Borrowings outstanding under credit facility | $ 35,000 | ||
Credit facility maturity date | Feb. 28, 2025 |
Fair Value Measurement and Fi_3
Fair Value Measurement and Financial Instruments - Schedule of Carrying Amounts and Fair Values of Financial Instruments (Details) - Money market funds - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Carrying Amount | ||
Assets | ||
Total assets | $ 69,405 | $ 91,236 |
Fair Value | ||
Assets | ||
Total assets | 69,405 | 91,236 |
Quoted Prices In Active Markets (Level 1) | ||
Assets | ||
Total assets | $ 69,405 | $ 91,236 |
Accounts Receivable - Compositi
Accounts Receivable - Composition of Accounts Receivable, Net (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Receivables [Abstract] | ||
Gross accounts receivable - trade | $ 13,754 | $ 9,168 |
Less: Allowances for doubtful accounts | (1,791) | (1,462) |
Accounts receivable, net | $ 11,963 | $ 7,706 |
Property and Equipment and Ca_3
Property and Equipment and Capitalized Software - Summary of Composition of Property and Equipment, Net (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | $ 5,026 | $ 3,757 |
Less: Accumulated depreciation | (2,917) | (2,537) |
Property and equipment, net | 2,109 | 1,220 |
Laboratory Equipment | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | 466 | 249 |
Office Equipment | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | 508 | 497 |
Computer Equipment and Software | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | 1,711 | 1,598 |
Manufacturing Equipment | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | 344 | 341 |
Leasehold Improvements | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | 1,422 | 471 |
Rental Equipment | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | 575 | 601 |
Property and equipment, net | $ 500 | $ 600 |
Property and Equipment and Ca_4
Property and Equipment and Capitalized Software - Additional Information (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Property Plant And Equipment [Line Items] | |||||
Depreciation and amortization expense | $ 0.4 | $ 0.2 | $ 1 | $ 0.8 | |
Prepaid expenses and other current assets | |||||
Property Plant And Equipment [Line Items] | |||||
Capitalized software cost, net | $ 3.7 | $ 3.7 | |||
Other assets | |||||
Property Plant And Equipment [Line Items] | |||||
Capitalized software cost, net | $ 2.5 |
Note Receivable (Details)
Note Receivable (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | |||
Jul. 14, 2022 | Sep. 29, 2021 | Sep. 30, 2022 | Sep. 30, 2022 | Apr. 29, 2022 | |
Senior Note | Maximum | |||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | |||||
Payment amount of notes receivable | $ 10 | ||||
Success T M S | |||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | |||||
Repayment of notes issued | $ 10.5 | ||||
Success T M S | Secured Promissory Note | |||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | |||||
Term of master sales agreement | 5 years | ||||
Term of notes receivable | 5 years | ||||
Principal amount of notes receivable | $ 10 | ||||
Success T M S | Secured Promissory Note | Other income, net | |||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | |||||
Interest income recognized | $ 0.5 | $ 1 | |||
Success T M S | Secured Promissory Note | Prime Rate | |||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | |||||
Interest rate (as a percent) | 6% |
Leases - Additional Information
Leases - Additional Information (Details) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2022 USD ($) ft² | Sep. 30, 2021 USD ($) | Sep. 30, 2022 USD ($) ft² | Sep. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | |
Leases [Line Items] | |||||
Lessee, finance lease, lease not yet commenced, description | The Company does not currently have any finance leases or executed leases that have not yet commenced. | ||||
Operating lease, rent expense, net | $ 200 | $ 200 | $ 600 | $ 400 | |
Operating lease, weighted-average remaining lease term | 5 years 3 months 18 days | 5 years 3 months 18 days | |||
Operating lease, weighted-average discount rate | 7.10% | 7.10% | |||
Carrying amount of lease receivables | $ 3,500 | $ 3,500 | |||
Unguaranteed residual assets | 0 | 0 | |||
Operating lease income | 70 | 30 | 200 | 200 | |
Property and equipment, net | $ 2,109 | $ 2,109 | $ 1,220 | ||
NeuroStar Advanced Therapy Systems | Minimum | |||||
Leases [Line Items] | |||||
Lessor sales-type lease, Term | 3 years | 3 years | |||
NeuroStar Advanced Therapy Systems | Maximum | |||||
Leases [Line Items] | |||||
Lessor sales-type lease, Term | 4 years | 4 years | |||
Headquarters and Office Equipment, Including Copiers | |||||
Leases [Line Items] | |||||
Area of lease facility | ft² | 32,000 | 32,000 | |||
Rental Equipment | |||||
Leases [Line Items] | |||||
Property and equipment, net | $ 500 | $ 500 | $ 600 | ||
Rental equipment depreciation expense | $ 20 | $ 10 | $ 70 | $ 30 | |
Charlotte, North Carolina | |||||
Leases [Line Items] | |||||
Area of lease facility | ft² | 9,600 | 9,600 |
Leases - Schedule of Supplement
Leases - Schedule of Supplemental Cash Flow Information as Lessee Related to Leases (Details) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Cash paid for amounts included in the measurement of lease liabilities: | ||
Operating cash flows from operating leases | $ 632 | $ 526 |
Leases - Schedule of Future Pay
Leases - Schedule of Future Payments of Operating Lease Liabilities (Details) $ in Thousands | Sep. 30, 2022 USD ($) |
Operating Lease Liabilities Payments Due [Abstract] | |
Remainder of 2022 | $ 209 |
2023 | 852 |
2024 | 875 |
2025 | 898 |
2026 | 921 |
Thereafter | 999 |
Total lease payments | 4,754 |
Less imputed interest | (825) |
Present value of operating lease liabilities | $ 3,929 |
Leases - Schedule of Profit Rec
Leases - Schedule of Profit Recognized on Sales-type Leases (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Sales Type Lease Lease Income [Abstract] | ||||
Profit recognized at commencement, net | $ 122 | $ 262 | $ 543 | $ 543 |
Total sales-type lease income | $ 122 | $ 262 | $ 543 | $ 543 |
Leases - Schedule of Maturity A
Leases - Schedule of Maturity Analysis of Undiscounted Lease Receivables Related to Sales-type Leases (Details) $ in Thousands | Sep. 30, 2022 USD ($) |
Sales Type And Direct Financing Leases Lease Receivable Fiscal Year Maturity [Abstract] | |
Remainder of 2022 | $ 605 |
2023 | 1,572 |
2024 | 858 |
2025 | 368 |
2026 | 88 |
Total sales-type lease receivables | $ 3,491 |
Prepaid Commission Expense - Ad
Prepaid Commission Expense - Additional Information (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Amortization Of Deferred Charges [Abstract] | ||||
Amortization period of deferred commissions | 7 years | |||
Amortization expense | $ 0.5 | $ 0.3 | $ 1.3 | $ 0.9 |
Accrued Expenses - Summary of C
Accrued Expenses - Summary of Composition of Accrued Expenses (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Payables And Accruals [Abstract] | ||
Compensation and related benefits | $ 8,022 | $ 5,090 |
Consulting and professional fees | 760 | 537 |
Research and development expenses | 637 | 388 |
Sales and marketing expenses | 246 | 268 |
Warranty | 337 | 306 |
Sales and other taxes payable | 558 | 664 |
Other | 933 | 980 |
Accrued expenses | $ 11,493 | $ 8,233 |
Deferred Revenue - Summary of P
Deferred Revenue - Summary of Percentages of Deferred Revenue by Year (Details) | Sep. 30, 2022 |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] | |
Revenue, remaining performance obligation | 100% |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]: 2022-10-01 | |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] | |
Revenue, remaining performance obligation | 25% |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 3 months |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]: 2023-01-01 | |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] | |
Revenue, remaining performance obligation | 40% |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 1 year |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]: 2024-01-01 | |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] | |
Revenue, remaining performance obligation | 25% |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 1 year |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]: 2025-01-01 | |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] | |
Revenue, remaining performance obligation | 8% |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 1 year |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]: 2026-01-01 | |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] | |
Revenue, remaining performance obligation | 2% |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 1 year |
Deferred Revenue - Additional I
Deferred Revenue - Additional Information (Details) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 USD ($) customer | Sep. 30, 2021 customer | Sep. 30, 2022 USD ($) customer | Sep. 30, 2021 customer | |
Deferred Revenue [Abstract] | ||||
Revenue recognized | $ | $ 0.4 | $ 2.2 | ||
Number of customer accounted for more than 10% of revenues | customer | 1 | 1 | 1 | 1 |
Debt - Summary of Composition o
Debt - Summary of Composition of Debt (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Debt Disclosure [Abstract] | ||
Outstanding principal | $ 35,000 | $ 35,000 |
Accrued final payment fees | 1,925 | 1,925 |
Less debt discounts | (1,166) | (1,590) |
Total debt, net | 35,759 | 35,335 |
Less current portion | (8,750) | |
Long-term debt, net | $ 27,009 | $ 35,335 |
Debt - Additional Information (
Debt - Additional Information (Details) $ in Thousands | 3 Months Ended | 9 Months Ended | ||||||
Dec. 08, 2020 USD ($) item | Mar. 02, 2020 USD ($) tranche | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Sep. 30, 2022 USD ($) | Mar. 31, 2022 USD ($) | Dec. 31, 2020 USD ($) | Mar. 31, 2017 USD ($) | |
Debt Instrument [Line Items] | ||||||||
Interest expense | $ 1,100 | $ 1,000 | $ 3,000 | |||||
Cash interest expense | 900 | 800 | 2,500 | |||||
Non-cash interest expense | $ 200 | $ 200 | $ 500 | |||||
Solar Capital Ltd | ||||||||
Debt Instrument [Line Items] | ||||||||
Amendment fee payable | $ 60 | $ 100 | ||||||
Solar Capital Ltd | Term A Loan | Maximum | ||||||||
Debt Instrument [Line Items] | ||||||||
Extended period of interest only term loan | 36 months | |||||||
Solar Capital Ltd | Term A Loan | Minimum | ||||||||
Debt Instrument [Line Items] | ||||||||
Extended period of interest only term loan | 24 months | |||||||
Solar Capital Ltd | Term A Loan and Term B Loan | ||||||||
Debt Instrument [Line Items] | ||||||||
Basis spread on variable rate | 1.66% | |||||||
Interest rate | 7.65% | |||||||
Interest-only period | 2022-03 | |||||||
Interest-only period upon achievement of revenues | 2023-02 | |||||||
Number of default events | 0 | |||||||
Line of credit facility, conversion to term loan, conditions | At the Company’s election, the interest only period may be extended through February 2023 if the Company satisfies a minimum net product revenue covenant through March 1, 2022 and no event of default shall have occurred. | |||||||
Solar Capital Ltd | $35.0 Million Credit Facility | ||||||||
Debt Instrument [Line Items] | ||||||||
Line of credit facility, maximum borrowing capacity | $ 35,000 | |||||||
Solar Capital Ltd | $35.0 Million Credit Facility | Term A Loan | ||||||||
Debt Instrument [Line Items] | ||||||||
Borrowings outstanding under credit facility | $ 35,000 | |||||||
Solar Capital Ltd | $50.0 Million Credit Facility | ||||||||
Debt Instrument [Line Items] | ||||||||
Line of credit facility, maximum borrowing capacity | $ 15,000 | $ 50,000 | ||||||
Borrowings outstanding under credit facility | $ 5,000 | |||||||
Term loans number of tranches | 3 | 2 | ||||||
Increase in final payment fees percentage upon extension interest only periods | 5.50% | |||||||
Trailing twelve month net product revenue first threshold limit to pay exit fee | $ 100,000 | |||||||
Trailing twelve month net product revenue Second threshold limit to pay exit fee | $ 125,000 | |||||||
Percentage of exit fee for liquidation, dissolution, winding up or change of control of the Company | 4.50% | |||||||
Percentage of exit fee upon achievement of any trailing twelve month revenues | 2.25% | |||||||
Percentage of exit fee upon achievement of both trailing twelve month revenues | 4.50% | |||||||
Capped exit fee percentage on term loan principal amount | 4.50% | |||||||
Solar Capital Ltd | $50.0 Million Credit Facility | Prepaid on or Before First Anniversary of Funding | ||||||||
Debt Instrument [Line Items] | ||||||||
Prepayment fees percentage | 3% | |||||||
Solar Capital Ltd | $50.0 Million Credit Facility | Prepaid After First and on or Before Second Anniversary of Funding | ||||||||
Debt Instrument [Line Items] | ||||||||
Prepayment fees percentage | 2% | |||||||
Solar Capital Ltd | $50.0 Million Credit Facility | Prepaid After Second Anniversary of Funding | ||||||||
Debt Instrument [Line Items] | ||||||||
Prepayment fees percentage | 1% | |||||||
Solar Capital Ltd | $50.0 Million Credit Facility | Term A Loan | ||||||||
Debt Instrument [Line Items] | ||||||||
Credit facility maturity date | Feb. 28, 2025 | |||||||
Solar Capital Ltd | $15 Million Credit Facility | Term B Loan | ||||||||
Debt Instrument [Line Items] | ||||||||
Line of credit facility, maximum borrowing capacity | $ 15,000 | |||||||
Line of credit facility, conversion to term loan, conditions | Under the Term B Loan portion of the Solar Facility, the Company is permitted to borrow, at its election, up to an aggregate amount of $15.0 million, (i) upon the Company achieving a specified amount of trailing twelve months net product revenue, and (ii) assuming there has been no event of default under the Solar Facility prior to such election. Once the net product revenue condition has been satisfied, the Company may make an election to borrow under the Term B Loan portion of the Solar Facility until the earlier of (a) December 15, 2021, (b) 30 days following achievement of the net product revenue condition or (c) the occurrence of an event of default. |
Common Stock - Additional Infor
Common Stock - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands | 9 Months Ended | |
Feb. 02, 2021 | Sep. 30, 2021 | |
Equity [Abstract] | ||
Common stock shares issued and sold | 5,566,000 | |
Public offering price | $ 15.50 | |
Net proceeds from initial public offering | $ 80,600 | $ 80,972 |
Common Stock - Summary of Commo
Common Stock - Summary of Common Stock Issued and Reserved for Issuance (Details) - shares shares in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Stockholders Deficit [Line Items] | ||
Shares of common stock issued | 27,060 | 26,395 |
Shares of common stock reserved for issuance for: | ||
Total shares of common stock issued and reserved for issuance | 34,749 | 32,929 |
Common stock warrants | ||
Shares of common stock reserved for issuance for: | ||
Shares of common stock reserved for issuance | 75 | 75 |
Stock options | ||
Shares of common stock reserved for issuance for: | ||
Shares of common stock reserved for issuance | 1,424 | 1,499 |
Restricted stock units | ||
Shares of common stock reserved for issuance for: | ||
Shares of common stock reserved for issuance | 4,060 | 2,124 |
Shares available for grant under stock incentive plan | ||
Shares of common stock reserved for issuance for: | ||
Shares of common stock reserved for issuance | 1,067 | 2,037 |
Shares available for sale under employee stock purchase plan | ||
Shares of common stock reserved for issuance for: | ||
Shares of common stock reserved for issuance | 1,063 | 799 |
Common Stock - Summary of Outst
Common Stock - Summary of Outstanding Common Stock Warrants (Details) - $ / shares shares in Thousands | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Class Of Warrant Or Right [Line Items] | ||
Warrants Outstanding | 75 | 75 |
Exercise Price $19.55 | ||
Class Of Warrant Or Right [Line Items] | ||
Warrants Outstanding | 14 | 14 |
Exercise Price | $ 19.55 | $ 19.55 |
Expiration Date | 2022-12 | 2022-12 |
Exercise Price $9.73 | ||
Class Of Warrant Or Right [Line Items] | ||
Warrants Outstanding | 20 | 20 |
Exercise Price | $ 9.73 | $ 9.73 |
Expiration Date | 2023-08 | 2023-08 |
Exercise Price. $9.73 | ||
Class Of Warrant Or Right [Line Items] | ||
Warrants Outstanding | 20 | 20 |
Exercise Price | $ 9.73 | $ 9.73 |
Expiration Date | 2024-03 | 2024-03 |
Exercise Price $9.73 | ||
Class Of Warrant Or Right [Line Items] | ||
Warrants Outstanding | 21 | 21 |
Exercise Price | $ 9.73 | $ 9.73 |
Expiration Date | 2024-12 | 2024-12 |
Loss Per Share - Schedule of Po
Loss Per Share - Schedule of Potentially Dilutive Securities Outstanding Excluded from Diluted Loss Per Share Calculation (Details) - shares shares in Thousands | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Stock options | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Potentially dilutive securities outstanding excluded from diluted loss per share | 1,424 | 1,567 |
Non-vested performance restricted stock units | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Potentially dilutive securities outstanding excluded from diluted loss per share | 395 | 395 |
Restricted stock units | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Potentially dilutive securities outstanding excluded from diluted loss per share | 3,665 | 1,647 |
Common stock warrants | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Potentially dilutive securities outstanding excluded from diluted loss per share | 75 | 75 |
Share-Based Compensation - Summ
Share-Based Compensation - Summary of Share-Based Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||||
Total | $ 2,178 | $ 1,961 | $ 6,633 | $ 6,166 |
Cost of Revenues | ||||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||||
Total | 35 | 23 | 94 | 56 |
Sales and Marketing | ||||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||||
Total | 1,074 | 515 | 3,258 | 1,608 |
General and Administrative | ||||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||||
Total | 939 | 1,368 | 2,950 | 4,368 |
Research and Development | ||||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||||
Total | $ 130 | $ 55 | $ 331 | $ 134 |
Share-Based Compensation - Addi
Share-Based Compensation - Additional Information (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | |||
Mar. 31, 2022 shares | Sep. 30, 2022 USD ($) shares | Sep. 30, 2021 USD ($) | Sep. 30, 2022 USD ($) installment shares | Sep. 30, 2021 USD ($) | Dec. 31, 2020 shares | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Share-based compensation expenses | $ 2,178 | $ 1,961 | $ 6,633 | $ 6,166 | ||
Intrinsic value of stock options exercised | 100 | |||||
Stock options | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Share-based compensation expenses | 200 | 200 | 500 | 600 | ||
Unrecognized compensation cost related to non-vested stock options | 700 | $ 700 | ||||
Non-vested awards not yet recognized weighted-average period for recognition | 1 year 4 months 24 days | |||||
Restricted Stock Units and Performance Restricted Stock Units | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Share-based compensation expenses | 2,000 | $ 1,800 | $ 6,100 | $ 5,500 | ||
Non-vested awards not yet recognized weighted-average period for recognition | 1 year 10 months 24 days | |||||
Unrecognized compensation cost related to non-vested restricted stock | $ 11,000 | $ 11,000 | ||||
Fair value of restricted stock vested | $ 2,200 | |||||
2018 Equity Incentive Plan | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Annual percentage increase in number of shares authorized for issuance | 4% | |||||
Vesting terms of stock options | stock options vest 25% upon the first anniversary of the date of grant and the remainder ratably monthly thereafter for 36 months. Restricted stock units generally vest ratably in three equal installments on the first, second and third anniversaries of the grant date. | |||||
Number of vesting installments | installment | 3 | |||||
Shares available for future issuance | shares | 600,000 | 600,000 | ||||
2018 Equity Incentive Plan | PRSUs | Common Stock | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Weighted average price, number of days trailing | 30 days | |||||
2018 Equity Incentive Plan | First Anniversary of Date of Grant | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Vesting percentage of stock options | 25% | |||||
2018 Equity Incentive Plan | Maximum | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Number of shares authorized for issuance | shares | 1,400,000 | 1,400,000 | ||||
Maximum contractual term of stock options | 10 years | |||||
2020 Inducement Incentive Plan | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Number of additional shares authorized for issuance | shares | 500,000 | |||||
Shares available for future issuance | shares | 500,000 | 500,000 | ||||
2020 Inducement Incentive Plan | Maximum | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Number of shares authorized for issuance | shares | 400,000 |
Share-Based Compensation - Su_2
Share-Based Compensation - Summary of Stock Option Activity (Details) - Stock options - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 9 Months Ended |
Sep. 30, 2022 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |
Number of Shares under Option, Outstanding, Beginning balance | 1,499 |
Number of Shares under Option, Exercised | (51) |
Number of Shares under Option, Forfeited | (24) |
Number of Shares under Option, Outstanding, Ending balance | 1,424 |
Number of Shares under Option, Exercisable | 913 |
Number of Shares under Option, Vested and expected to vest | 1,424 |
Weighted-average Exercise Price per Option, Outstanding, Beginning balance | $ 4.01 |
Weighted-average Exercise Price per Option, Exercised | 1.01 |
Weighted-average Exercise Price per Option, Forfeited | 13.41 |
Weighted-average Exercise Price per Option, Outstanding, Ending balance | 3.96 |
Weighted-average Exercise Price per Option, Exercisable | 4.62 |
Weighted-average Exercise Price per Option, Vested and expected to vest | $ 3.96 |
Weighted-average Remaining Contractual Life, Outstanding | 7 years 2 months 12 days |
Weighted-average Remaining Contractual Life, Exercisable | 6 years 10 months 24 days |
Weighted-average Remaining Contractual Life, Vested and expected to vest | 7 years 2 months 12 days |
Aggregate Intrinsic Value, Outstanding | $ 1,260 |
Aggregate Intrinsic Value, Exercisable | 708 |
Aggregate Intrinsic Value, Vested and expected to vest | $ 1,260 |
Share-Based Compensation - Su_3
Share-Based Compensation - Summary of Restricted Stock Units and Performance Restricted Stock Unit Activity (Details) shares in Thousands | 9 Months Ended |
Sep. 30, 2022 $ / shares shares | |
Restricted stock units | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |
Non-vested, Beginning balance | shares | 1,729 |
Granted | shares | 2,775 |
Vested | shares | (613) |
Forfeited | shares | (226) |
Non-vested, Ending balance | shares | 3,665 |
Weighted-average Grant-date Fair Value, Non-vested, Beginning balance | $ / shares | $ 7.29 |
Weighted-average Grant-date Fair Value, Granted | $ / shares | 3.32 |
Weighted-average Grant-date Fair Value, Vested | $ / shares | 7.64 |
Weighted-average Grant-date Fair Value, Forfeited | $ / shares | 6.12 |
Weighted-average Grant-date Fair Value, Non-vested, Ending balance | $ / shares | $ 4.29 |
Performance Restricted Stock Units | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |
Non-vested, Beginning balance | shares | 395 |
Non-vested, Ending balance | shares | 395 |
Weighted-average Grant-date Fair Value, Non-vested, Beginning balance | $ / shares | $ 6.77 |
Weighted-average Grant-date Fair Value, Non-vested, Ending balance | $ / shares | $ 6.77 |
Share-Based Compensation - Su_4
Share-Based Compensation - Summary of Inputs and Assumptions used to Estimated Grant-date Fair Value of Performance Restricted Stock Unit (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2021 | Feb. 02, 2021 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Closing price of common stock | $ 15.50 | |
Performance Restricted Stock Units | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Closing price of common stock | $ 15.92 | |
Risk-free interest rate | 1.15% | |
Expected volatility | 99.70% |
Geographical Segment Informat_3
Geographical Segment Information - Additional Information (Details) | 9 Months Ended |
Sep. 30, 2022 segment | |
Segments Geographical Areas [Abstract] | |
Number of operating business segment | 1 |
Geographical Segment Informat_4
Geographical Segment Information - Summary of Revenue Generated in Geographic Regions for Years Indicated (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Segment Reporting Information [Line Items] | ||||
Revenues | $ 16,498 | $ 13,799 | $ 47,008 | $ 40,290 |
Revenue | Geographic Concentration | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | $ 16,498 | $ 13,799 | $ 47,008 | $ 40,290 |
Percentage of Revenues | 100% | 100% | 100% | 100% |
Revenue | United States | Geographic Concentration | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | $ 16,244 | $ 13,280 | $ 45,893 | $ 38,891 |
Percentage of Revenues | 98% | 96% | 98% | 97% |
Revenue | International | Geographic Concentration | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | $ 254 | $ 519 | $ 1,115 | $ 1,399 |
Percentage of Revenues | 2% | 4% | 2% | 3% |
Geographical Segment Informat_5
Geographical Segment Information - Summary of Revenue Generated in Product Category for Years Indicated (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Segment Reporting Information [Line Items] | ||||
Revenues | $ 16,498 | $ 13,799 | $ 47,008 | $ 40,290 |
Product Category | United States | Revenue | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | $ 16,244 | $ 13,280 | $ 45,893 | $ 38,891 |
Percentage of Revenues | 100% | 100% | 100% | 100% |
Product Category | United States | Revenue | NeuroStar Advanced Therapy System | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | $ 3,934 | $ 2,612 | $ 11,959 | $ 6,945 |
Percentage of Revenues | 24% | 20% | 26% | 18% |
Product Category | United States | Revenue | Treatment Sessions | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | $ 11,864 | $ 10,259 | $ 32,627 | $ 30,688 |
Percentage of Revenues | 73% | 77% | 71% | 79% |
Product Category | United States | Revenue | Other | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | $ 446 | $ 409 | $ 1,307 | $ 1,258 |
Percentage of Revenues | 3% | 3% | 3% | 3% |
Product Category | International | Revenue | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | $ 254 | $ 519 | $ 1,115 | $ 1,399 |
Percentage of Revenues | 100% | 100% | 100% | 100% |
Product Category | International | Revenue | NeuroStar Advanced Therapy System | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | $ 96 | $ 306 | $ 460 | $ 797 |
Percentage of Revenues | 38% | 59% | 41% | 57% |
Product Category | International | Revenue | Treatment Sessions | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | $ 31 | $ 90 | $ 214 | $ 235 |
Percentage of Revenues | 12% | 17% | 19% | 17% |
Product Category | International | Revenue | Other | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | $ 127 | $ 123 | $ 441 | $ 367 |
Percentage of Revenues | 50% | 24% | 40% | 26% |
Severance - Additional Informat
Severance - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Restructuring Cost And Reserve [Line Items] | |||||
Accrued liabilities | $ 11,493 | $ 11,493 | $ 8,233 | ||
Transition Separation Agreement | |||||
Restructuring Cost And Reserve [Line Items] | |||||
Restructuring charges | 0 | $ 300 | 200 | $ 500 | |
Accrued liabilities | $ 0 | 0 | $ 100 | ||
Termination Benefits | Transition Separation Agreement | |||||
Restructuring Cost And Reserve [Line Items] | |||||
Payments for restructuring | $ 400 | $ 1,100 |
Risks and Uncertainties - Infor
Risks and Uncertainties - Information About Significant Customers (Details) - USD ($) $ in Thousands | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Concentration Risk [Line Items] | |||
Accounts receivable | $ 11,963 | $ 7,706 | |
Significant Customers | |||
Concentration Risk [Line Items] | |||
Accounts receivable | 4,886 | ||
Customer 1 | |||
Concentration Risk [Line Items] | |||
Accounts receivable | 4,886 | ||
Revenue | Customer concentration risk | Significant Customers | |||
Concentration Risk [Line Items] | |||
Revenues | $ 9,183 | $ 8,759 | |
Concentration of risk (as a percent) | 20% | 22% | |
Revenue | Customer concentration risk | Customer 1 | |||
Concentration Risk [Line Items] | |||
Revenues | $ 9,183 | $ 8,759 | |
Concentration of risk (as a percent) | 20% | 22% |